1Hamroff G,Blaufarb I,Mancini D,et al.Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treat with angiotensin-converting enzyme inhibitors for heart failure[].Journal of Cardiovascular Pharmacology.1997
2Krombach RS,Clair MJ,Hendrick JW,et al.Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns[].Cardiovascular Research.1998
3Baruch L,Anand I,Cohen IS,et al.Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patient with heart failure[].Circulation.1999
4Lang RM,Elkayam U,Yellen LG,et al.Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure[].Journal of the American College of Cardiology.1997
5McKelvie RA,Yusuf S,Pericak D,et al.Comparison of candesartan,enalapril, and their combination in congestive heart failure[].Circulation.1999
6Hamroff G,Blaufarb I,Mancini D,et al.Maximally recommended doses of ACE inhibitors do not completely prevent ACE-mediated formation of Ang II in CHF[].Circulation.2000
7Dickstein K,Chang P,Willenheimer R,et al.Comparison of the effects of Losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure[].Journal of the American College of Cardiology.1995
8Crozier I,Ikram H,Awan N,et al.Losartan in heart failure:hemodynamic effects and tolerability[].Circulation.1995
9Cohn JN,Tognoni G.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[].The New England Journal of Medicine.2001
10Havranek EP,Thomas I,Smith WB,et al.Dose-related beneficial longterm hemodynamic and clinical efficacy of irbesartan in heart failure[].Journal of the American College of Cardiology.1999
